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Abstract
Indatuximab ravtansine is a monoclonal antibody-linked cytotoxic agent that specifically targets CD138-expressing
cells. Monotherapy has been shown to significantly inhibit multiple myeloma tumour growth in vivo and improve
host survival. Here, we show that in most cell lines tested, indatuximab ravtansine acts additively or even
synergistically with clinically approved therapies for treatment of multiple myeloma. In addition, in vivo mouse
xenograft models confirmed the activity of indatuximab ravtansine in combination with lenalidamide and
lenalidomide/dexamethasone. Indatuximab ravtansine may therefore be a suitable combination partner for multiple
myeloma, and a clinical study is ongoing.
Keywords: Multiple myeloma, Pre-clinical, Indatuximab ravtansine, Drug combination, Tumour regression
Letter
Multiple myeloma is a highly aggressive malignancy
characterised by the clonal proliferation of plasma cells
in the bone marrow and associated organ damage result-
ing from the presence of monoclonal proteins (M-pro-
teins) in the blood or urine. The cell surface heparan
sulphate proteoglycan CD138 (syndecan-1) is a trans-
membrane protein receptor for the extracellular matrix
(ECM) that mediates cell-cell adhesion via interactions
with heparan-binding molecules. In multiple myeloma,
CD138 has been shown to be a co-receptor for multiple
myeloma growth factors [1]. CD138 is overexpressed on
malignant plasma cells and is used as a primary diagnos-
tic marker for multiple myeloma [2]. Indatuximab
ravtansine (BT062) is an antibody-drug conjugate based
on a murine/human chimeric form of B-B4 (specific for
CD138), linked to the maytansinoid drug DM4 by
disulphide bonds and has previously been shown to
significantly inhibit multiple myeloma tumour growth in
vivo and to prolong host survival in xenograft mouse
models of human multiple myeloma [3]. However, treat-
ment of multiple myeloma typically involves combin-
ation therapy [4–6]. Since indatuximab ravtansine has a
unique mode of action that is different to that of stand-
ard of care therapies, it might be a suitable combination
partner with approved drugs for the treatment of mul-
tiple myeloma. Therefore, the effects of indatuximab rav-
tansine in combination with some clinically approved
therapies for multiple myeloma were investigated in
both in vitro and in vivo models (Additional file 1:
Methods). In vitro, anti-tumour-effect studies in RPMI
8226, MOLP-8 and U266 cell lines demonstrated significant
CD138 expression and sensitivity to indatuximab ravtansine
(Fig. 1a–c, Additional file 2: Figure S1; IC50 200 pM, RPMI
8226; 40 pM, MOLP-8; 20 pM, U266). Further in vitro
studies investigated the cytotoxic effects of potential drug
combinations. Additive or synergistic effects were observed
for indatuximab ravtansine in combination with bortezo-
mib, thalidomide, lenalidomide, melphalan or dexametha-
sone in vitro in most cell lines (Fig. 1d).
Mouse xenograft models (MOLP-8 and MMXF L363)
were then used to investigate in vivo the anti-tumour ac-
tivity of combination therapy with indatuximab ravtan-
sine and clinically approved myeloma drugs. In MOLP-8
xenograft mouse models, indatuximab ravtansine exhib-
ited a dose-response effect on tumour regression and
this effect was enhanced when assessed in combination
with lenalidomide. Lenolidamide (and later in combin-
ation with dexamethasone) was chosen for in vivo
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Fig. 1 Cytotoxic effects of indatuximab ravtansine. a Sensitivity of RPMI 8226, b MOLP-8 and c U266 cells to indatuximab ravtansine
(IR; 1 pM–100 nM) was determined by Alamar Blue proliferation assay and expressed as survival fractions. d Drug combinations of indatuximab
ravtansine with bortezomib, thalidomide, lenalidomide, melphalan and dexamethasone
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studies based on the in vitro results and due to it being
an established, clinically approved treatment for multiple
myeloma. The greatest effects on MOLP-8 tumour
regression were observed with 21.2 mg/kg/day indatuxi-
mab ravtansine and 100 mg/kg/day lenalidomide (Fig. 2a,
Additional file 3: Table S1).
The anti-tumour activity of indatuximab ravtansine
was also investigated in combination with both lenalido-
mide and dexamethasone in an aggressive xenograft
model using the plasma cell myeloma cell line MMXF
L363. In this xenograft model, indatuximab ravtansine
treatment alone (2 and 4 mg/kg), as well as the combin-
ation of lenalidomide and dexamethasone resulted in
tumour growth delay (Fig. 2b). When assessed alone,
single-agent indatuximab ravtansine at a dose of 4 mg/
kg achieved similar anti-tumour activity as the combin-
ation of lenalidomide and dexamethasone. Furthermore,
a stronger effect on tumour growth was observed when
indatuximab ravtansine 4 mg/kg was combined with
lenalidomide and dexamethasone (Fig. 2b). Treatment
with indatuximab ravtansine was well tolerated.
Single-agent indatuximab ravtansine has already been
shown to have clinical activity in patients with relapsed/
refractory multiple myeloma [7, 8]. These pre-clinical
data provide a basis for the development of indatuximab
ravtansine in combination with clinically approved
anti-myeloma drugs such as lenalidomide and dexa-
methasone and in light of these results, a clinical
Fig. 2 Anti-tumour activity in MOLP-8 and MMXF L363 tumours. a Dose-response anti-tumour activity (median tumour volume) in female CB.17
SCID mice inoculated with MOLP-8 multiple myeloma xenografts with control PBS; or indatuximab ravtansine (IR; 5.3, 10.6 or 21.2 mg/kg body
weight); or lenalidomide (Len; 100 mg/kg/day); or combination of indatuximab ravtansine plus lenalidomide. Anti-tumour activity was evaluated
by comparison of maximum tumour volume inhibition compared to control. b Anti-tumour activity (median tumour volume) in female CB.17
SCID mice inoculated with plasma cell leukaemia model MMXF L363 multiple myeloma xenografts with control (PBS); or indatuximab ravtansine
(IR; 2 or 4 mg/kg/day); or lenalidomide (Len; 20 mg/kg/day) and dexamethasone (1.25 mg/kg/day); or combination of indatuximab ravtansine plus
lenalidomide and dexamethasone
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phase I/IIa study has been initiated to evaluate the
safety and efficacy of indatuximab ravtansine in combin-
ation with lenalidomide and dexamethasone in patients
with relapsed/refractory multiple myeloma. Promising ini-
tial results from this study have been reported [9], and the
trial is currently ongoing.
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